Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 41 citing articles:

Angiotensin‐converting enzyme 2 (ACE2), SARS‐CoV‐2 and the pathophysiology of coronavirus disease 2019 (COVID‐19)
Arno R. Bourgonje, Amaal Eman Abdulle, Wim Timens, et al.
The Journal of Pathology (2020) Vol. 251, Iss. 3, pp. 228-248
Open Access | Times Cited: 999
Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity
Yared Hailemichael, Daniel H. Johnson, Noha Abdel‐Wahab, et al.
Cancer Cell (2022) Vol. 40, Iss. 5, pp. 509-523.e6
Open Access | Times Cited: 222
COVID-19: Pulmonary and Extra Pulmonary Manifestations
Islam Elrobaa, Karl J. New
Frontiers in Public Health (2021) Vol. 9
Open Access | Times Cited: 118
Biomarkers of Checkpoint Inhibitor Induced Immune-Related Adverse Events—A Comprehensive Review
Josefien W. Hommes, Rik J. Verheijden, Karijn P.M. Suijkerbuijk, et al.
Frontiers in Oncology (2021) Vol. 10
Open Access | Times Cited: 104
Blueprint for cancer research: Critical gaps and opportunities
Lynne W. Elmore, Susanna F. Greer, Elvan C. Daniels, et al.
CA A Cancer Journal for Clinicians (2020) Vol. 71, Iss. 2, pp. 107-139
Open Access | Times Cited: 88
Immune‐related adverse events are associated with improved response, progression‐free survival, and overall survival for patients with head and neck cancer receiving immune checkpoint inhibitors
Corey C. Foster, Marcus Couey, Sara Kochanny, et al.
Cancer (2021) Vol. 127, Iss. 24, pp. 4565-4573
Open Access | Times Cited: 56
MicroRNA-146a regulates immune-related adverse events caused by immune checkpoint inhibitors
Dominik Marschner, Martina Falk, Nóra Rebeka Jávorniczky, et al.
JCI Insight (2020) Vol. 5, Iss. 6
Open Access | Times Cited: 70
Immunopathogenesis of Immune Checkpoint Inhibitor-Related Adverse Events: Roles of the Intestinal Microbiome and Th17 Cells
Ronald Anderson, Annette J. Theron, Bernardo L. Rapoport
Frontiers in Immunology (2019) Vol. 10
Open Access | Times Cited: 65
Mécanismes physiopathologiques des effets secondaires des immunothérapies par anticorps anti-CTLA-4, anti-PD-1 et anti-PD-L1 dans le traitement du cancer
Tilda Passat, Yann Touchefeu, Nadine Gervois, et al.
Bulletin du Cancer (2018) Vol. 105, Iss. 11, pp. 1033-1041
Closed Access | Times Cited: 60
Immune-Related Adverse Events: A Case-Based Approach
Caoilfhionn M Connolly, Kalindi Bambhania, Jarushka Naidoo
Frontiers in Oncology (2019) Vol. 9
Open Access | Times Cited: 37
Immune‐related adverse events of antibody‐based biological medicines in cancer therapy
Deepa Rajagopal, Elliot MacLeod, Diana Corogeanu, et al.
Journal of Cellular and Molecular Medicine (2024) Vol. 28, Iss. 13
Open Access | Times Cited: 4
Clinical Characteristics of Toxicities of Immune Checkpoint Inhibitors and Their Impact on Efficacy in Solid Cancers: An Analysis of Real-World Data in Moroccan Patients
Badiaa Batlamous, Sihame Lkhoyaali, Loubna Omri, et al.
JCO Global Oncology (2025), Iss. 11
Open Access
CTLA-4 regulates human Natural Killer cell effector functions
Vassilios Lougaris, Giovanna Tabellini, Manuela Baronio, et al.
Clinical Immunology (2018) Vol. 194, pp. 43-45
Open Access | Times Cited: 33
Immune signature as predictive marker for response to checkpoint inhibitor immunotherapy and overall survival in melanoma
Franziska K. Krebs, Emily R. Trzeciak, Sophia Zimmer, et al.
Cancer Medicine (2021) Vol. 10, Iss. 5, pp. 1562-1575
Open Access | Times Cited: 23
Dormant pathogenic CD4+ T cells are prevalent in the peripheral repertoire of healthy mice
Anna Cebula, Michal Kuczma, Edyta Szurek, et al.
Nature Communications (2019) Vol. 10, Iss. 1
Open Access | Times Cited: 24
Association Between Succinate Receptor SUCNR1 Expression and Immune Infiltrates in Ovarian Cancer
Jiawen Zhang, Qinyi Zhang, Yongbin Yang, et al.
Frontiers in Molecular Biosciences (2020) Vol. 7
Open Access | Times Cited: 21
Immunotherapy-based combination strategies for treatment of gastrointestinal cancers: current status and future prospects
Chenfei Zhou, Jun Zhang
Frontiers of Medicine (2019) Vol. 13, Iss. 1, pp. 12-23
Open Access | Times Cited: 19
Gut Microbiome and Immune Checkpoint Inhibitor-Induced Enterocolitis
Hamzah Abu‐Sbeih, Yinghong Wang
Digestive Diseases and Sciences (2020) Vol. 65, Iss. 3, pp. 797-799
Closed Access | Times Cited: 17
Embracing cancer immunotherapy with vital micronutrients
Raymond C-F Yuen, S.Y. Tsao
World Journal of Clinical Oncology (2021) Vol. 12, Iss. 9, pp. 712-724
Open Access | Times Cited: 13
The association between immune-related adverse events and the prognosis of solid cancer patients treated with immunotherapy: a systematic review and meta-analysis
Huilin Xu, Ximing Xu, Wei Ge, et al.
Therapeutic Advances in Medical Oncology (2020) Vol. 12, pp. 175883592098054-175883592098054
Open Access | Times Cited: 13
Contribution of the Skin–Gut Axis to Immune-Related Adverse Events with Multi-System Involvement
Alyce Mei-Shiuan Kuo, Lukas Kraehenbuehl, Stephanie King, et al.
Cancers (2022) Vol. 14, Iss. 12, pp. 2995-2995
Open Access | Times Cited: 8
Harnessing NK Cell Checkpoint-Modulating Immunotherapies
Sachin Kumar Singh Chauhan, Ulrike Koehl, Stephan Kloeß
Cancers (2020) Vol. 12, Iss. 7, pp. 1807-1807
Open Access | Times Cited: 11
The Underappreciated Role of the Humoral Immune System and B Cells in Tumorigenesis and Cancer Therapeutics: A Review
Victor E. Chen, Benjamin A. Greenberger, James M. Taylor, et al.
International Journal of Radiation Oncology*Biology*Physics (2020) Vol. 108, Iss. 1, pp. 38-45
Closed Access | Times Cited: 10
Supportive care for new cancer therapies
Bernardo L. Rapoport, Tim Cooksley, Douglas B. Johnson, et al.
Current Opinion in Oncology (2021) Vol. 33, Iss. 4, pp. 287-294
Closed Access | Times Cited: 9
Minimal change disease in a patient receiving checkpoint inhibition: Another possible manifestation of kidney autoimmunity?
Erin E Vaughan, E. Connolly, Mun N. Hui, et al.
Cancer Reports (2020) Vol. 3, Iss. 5
Open Access | Times Cited: 9
Page 1 - Next Page

Scroll to top